Literature DB >> 27180007

Administration of probiotic kefir to mice with Clostridium difficile infection exacerbates disease.

Jennifer K Spinler1, Aaron Brown2, Caná L Ross2, Prapaporn Boonma2, Margaret E Conner3, Tor C Savidge2.   

Abstract

Lifeway(®) kefir, a fermented milk product containing 12 probiotic organisms, is reported to show promise as an alternative to fecal microbiota transplantation for recurrent Clostridium difficile infection (CDI). We employed a murine CDI model to study the probiotic protective mechanisms and unexpectedly determined that kefir drastically increased disease severity. Our results emphasize the need for further independent clinical testing of kefir as alternative therapy in recurrent CDI.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Fecal microbiota transplantation; Kefir; Probiotic; Toxin

Mesh：

Year:  2016        PMID： 27180007      PMCID： PMC4969211          DOI： 10.1016/j.anaerobe.2016.05.008

Source DB:  PubMed          Journal:  Anaerobe        ISSN： 1075-9964            Impact factor:   3.331


  38 in total

1.  FDA slaps regs on fecal transplants. Increased steps for C. diff treatment draw mixed reactions from providers.

Authors:  Maureen McKinney
Journal:  Mod Healthc       Date:  2013-05-27

Review 2.  Clostridium difficile infection.

Authors:  Daniel A Leffler; J Thomas Lamont
Journal:  N Engl J Med       Date:  2015-04-16       Impact factor: 91.245

3.  Pathway to Prevention of Nosocomial Clostridium difficile Infection.

Authors:  Ellie J C Goldstein; Stuart Johnson; Pierre-Jean Maziade; Lynne V McFarland; William Trick; Linda Dresser; Mathieu Millette; Hadi Mazloum; Donald E Low
Journal:  Clin Infect Dis       Date:  2015-05-15       Impact factor: 9.079

Review 4.  Clostridium difficile infection: A brief update on emerging therapies.

Authors:  Erika J Goldberg; Sumit Bhalodia; Sherin Jacob; Hatil Patel; Ken V Trinh; Blessy Varghese; Jungmo Yang; Sean R Young; Robert B Raffa
Journal:  Am J Health Syst Pharm       Date:  2015-06-15       Impact factor: 2.637

Review 5.  Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.

Authors:  Stuart Johnson
Journal:  J Infect       Date:  2009-04-05       Impact factor: 6.072

6.  Improved extraction of PCR-quality community DNA from digesta and fecal samples.

Authors:  Zhongtang Yu; Mark Morrison
Journal:  Biotechniques       Date:  2004-05       Impact factor: 1.993

Review 7.  Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children.

Authors:  Joshua Z Goldenberg; Stephanie S Y Ma; Jane D Saxton; Mark R Martzen; Per O Vandvik; Kristian Thorlund; Gordon H Guyatt; Bradley C Johnston
Journal:  Cochrane Database Syst Rev       Date:  2013-05-31

8.  Multistate point-prevalence survey of health care-associated infections.

Authors:  Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

9.  Feces transplantation for recurrent Clostridium difficile infection: US experience and recommendations.

Authors:  Johan S Bakken
Journal:  Microb Ecol Health Dis       Date:  2015-05-29

10.  Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile.

Authors:  Charlie G Buffie; Vanni Bucci; Richard R Stein; Peter T McKenney; Lilan Ling; Asia Gobourne; Daniel No; Hui Liu; Melissa Kinnebrew; Agnes Viale; Eric Littmann; Marcel R M van den Brink; Robert R Jenq; Ying Taur; Chris Sander; Justin R Cross; Nora C Toussaint; Joao B Xavier; Eric G Pamer
Journal:  Nature       Date:  2014-10-22       Impact factor: 49.962
View more
  8 in total

1.  Our Microbiome: On the Challenges, Promises, and Hype.

Authors:  Sara Federici; Jotham Suez; Eran Elinav
Journal:  Results Probl Cell Differ       Date:  2020

2.  Probiotic Product Enhances Susceptibility of Mice to Cryptosporidiosis.

Authors:  Bruno C M Oliveira; Giovanni Widmer
Journal:  Appl Environ Microbiol       Date:  2018-10-17       Impact factor: 4.792

Review 3.  Control of Clostridium difficile Infection by Defined Microbial Communities.

Authors:  James Collins; Jennifer M Auchtung
Journal:  Microbiol Spectr       Date:  2017-09

Review 4.  Probiotics as adjunctive therapy for preventing Clostridium difficile infection - What are we waiting for?

Authors:  Jennifer K Spinler; Caná L Ross; Tor C Savidge
Journal:  Anaerobe       Date:  2016-05-13       Impact factor: 3.331

5.  Next-Generation Probiotics Targeting Clostridium difficile through Precursor-Directed Antimicrobial Biosynthesis.

Authors:  Jennifer K Spinler; Jennifer Auchtung; Aaron Brown; Prapaporn Boonma; Numan Oezguen; Caná L Ross; Ruth Ann Luna; Jessica Runge; James Versalovic; Alex Peniche; Sara M Dann; Robert A Britton; Anthony Haag; Tor C Savidge
Journal:  Infect Immun       Date:  2017-09-20       Impact factor: 3.441

Review 6.  Effects of gut microbiota and probiotics on Alzheimer's disease.

Authors:  Libing Guo; Jiaxin Xu; Yunhua Du; Weibo Wu; Wenjing Nie; Dongliang Zhang; Yuling Luo; Huixian Lu; Ming Lei; Songhua Xiao; Jun Liu
Journal:  Transl Neurosci       Date:  2021-12-27       Impact factor: 1.757

Review 7.  The Effects of Kefir and Kefir Components on Immune and Metabolic Physiology in Pre-Clinical Studies: A Narrative Review.

Authors:  Tyler Culpepper
Journal:  Cureus       Date:  2022-08-08

8.  The Initial Gut Microbiota and Response to Antibiotic Perturbation Influence Clostridioides difficile Clearance in Mice.

Authors:  Sarah Tomkovich; Joshua M A Stough; Lucas Bishop; Patrick D Schloss
Journal:  mSphere       Date:  2020-10-21       Impact factor: 4.389
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.